Important Information

This section of the website (the “Microsite”) of Mereo BioPharma Group plc (the “Company”) has been prepared solely for your information and for the purpose of providing background information on the Company, its business, the upcoming general meeting of the Company’s shareholders, and the industry in which the Company operates or any particular aspect thereof. For further information, please see the shareholder circular published by the Company in connection with the General Meeting which is available at www.mereobiopharma.com/GeneralMeeting2022 or at sec.gov.

The information contained in the Microsite has not been independently verified and no representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its subsidiaries, or any of any such person’s directors, officers, employees, agents, affiliates or advisers, as to, and no reliance should be placed on, the accuracy, completeness or fairness of the information or opinions contained in the Microsite and no responsibility or liability is assumed by any such persons for any such information or opinions or for any errors or omissions. All information presented or contained in the Microsite is subject to verification, correction, completion and change without notice. In making available the Microsite, none of the Company or any of its subsidiaries, or any of any such person’s directors, officers, employees, agents, affiliates or advisers, undertakes any obligation to amend, correct or update the information contained in the Microsite or to provide the recipient with access to any additional information that may arise in connection with it. Accordingly, undue reliance should not be placed on any of the data contained in the Microsite.

Forward-Looking Statements

The Microsite and the information in it contain “forward-looking statements.” All statements other than statements of historical fact are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements relate to future events, including, but not limited to, statements regarding future clinical development, efficacy, safety and therapeutic potential of clinical product candidates, including expectations as to reporting of data, conduct and timing and potential future clinical activity and milestones and expectations regarding the initiation, design and reporting of data from clinical trials. Forward-looking statements are often identified by the words “believe,” “expect,” “anticipate,” “plan,” “intend,” “foresee,” “should,” “would,” “could,” “may,” “estimate,” “outlook” and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company’s current expectations, beliefs and assumptions concerning future developments and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of its latest Annual Report on Form 20-F, reports on Form 6-K and other documents furnished or filed from time to time by the Company with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law. The Microsite and the information in it also contain estimates, projections and other information concerning the Company’s business and the markets for the Company’s product candidates, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events, or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, the Company obtained this industry, business, market and other data from reports, research surveys, clinical trials studies and similar data prepared by market research firms and other third parties, from industry, medical and general publications, and from government data and similar sources.


Working with patients

Rare Disease Day Logo Med (1)

Rare Disease Day 2023

To mark international Rare Disease Day this year we hosted Thines Ganeshamoorthy, Trustee at the Brittle Bone Society, and Professor Richard Keen, Consultant in Metabolic Bone Diseases, Royal National Orthopaedic Hospital, at the Mereo Office in London to share perspectives on aspects of living with Osteogenesis Imperfecta (OI). 

Click here to find out more.

Working With You Images Patients 1

We know that there is nothing for you, without you. We recognize the value in collaborating with patients and patient communities – particularly in rare diseases, where you are often the experts in your own or your family’s condition.

That’s why we actively seek out opportunities to include your voice and actively work to foster meaningful relationships with community representation groups. We also believe that it is important for all of our team members to understand and feel the impact that our work could have on the lives of patients, which is why we provide our team with opportunities to connect with patient communities.

Our Pipeline Images Core Pro 2 Alvelestat

Mereo and the Alpha-1 community

We engage with Alpha community representative organizations such as Alpha-1 Foundation, Alpha-1 Global, Alpha-1 UK Support Group.  This enables us to gain first-hand understanding of the experiences of Alphas and to ensure that their perspectives are reflected in our work in the most appropriate and inclusive way.

In 2021, alongside European AATD community groups we launched the What is Alpha-1? campaign to improve awareness of AATD to support the potential for improved diagnosis, treatment and care.  And, as part of our ongoing engagement, we invited a Committee Member of the Alpha-1 UK Support Group and a person living with AATD, to our offices to share their personal perspectives on living with the condition.

Mereo team members regularly participate in conferences and meetings organised by the Alpha-1 community, at a global, regional and country level.  

Working With You Images Patients 3

Mereo and the OI community

We engage  with OI community representative organizations at the above-country, regional level, such as the  Osteogenesis Imperfecta Federation Europe (OIFE) and Osteogenesis Imperfecta Foundation (OIF).

This engagement enables us to secure that the perspectives of the OI community are taken into consideration as we plan our activities on the pathway to support potential new therapeutic options for OI.

As part of our approach of listening to people from the OI community on an ongoing basis, we regularly invite people representing OI organisations to come to our offices and share their perspectives with the Mereo team.  Over recent years, we have welcomed an adult living with OI to our offices and, more recently, the President of the OIFE, as well as a Board Member who is also a parent of a child with OI, who joined our annual Rare Disease Day event in 2022.

Mereo team members regularly attend meetings and conferences organised by the OI community in the US and Europe, as well as individual country meetings organised by OIFE member organisations.

In 2021, Mereo initiated the development and delivery of the IMPACT Survey, a joint initiative with the Osteogenesis Imperfecta Foundation (OIF) and the Osteogenesis Imperfecta Federation Europe (OIFE) together with their member organisations. The survey, which was rolled out globally, has resulted in the largest global gathering of data to date about the impact that OI has on people with OI, their families and caregivers, will be used to support future collaborative work on better diagnosis, treatment, and care and to support the timely evaluation and potential availability of new treatments.


Thank you to Mereo for inviting us to talk about OI from the perspective of people who have OI themselves, and to provide advice from the patient organization perspective. We are thrilled that you are interested in hearing the patient’s voices and want to work with us in such a constructive way.”

Ingunn Westerheim, President of Osteogenesis Imperfecta Federation Europe (OIFE)